Debra Richardson to Paclitaxel
This is a "connection" page, showing publications Debra Richardson has written about Paclitaxel.
Connection Strength
1.535
-
Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299.
Score: 0.579
-
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
Score: 0.556
-
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
Score: 0.134
-
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6.
Score: 0.072
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
Score: 0.043
-
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
Score: 0.040
-
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
Score: 0.025
-
Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012 Mar; 55(1):131-55.
Score: 0.023
-
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
Score: 0.021
-
Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31.
Score: 0.021
-
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009 Oct; 19(7):1195-8.
Score: 0.020